<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3589">
  <stage>Registered</stage>
  <submitdate>27/06/2012</submitdate>
  <approvaldate>27/06/2012</approvaldate>
  <nctid>NCT01637259</nctid>
  <trial_identification>
    <studytitle>MARCH Renal Substudy</studytitle>
    <scientifictitle>Maraviroc Switch Collaborative Study Renal Substudy</scientifictitle>
    <utrn />
    <trialacronym>MARCHrenal</trialacronym>
    <secondaryid>MARCH-Kirby renal</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Proteinuria</healthcondition>
    <healthcondition>HIV</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors
Treatment: drugs - Arm 2 boosted protease inhibitors and maraviroc
Treatment: drugs - Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc

Active Comparator: NRTI + PI - arm 1

Active Comparator: PI + maraviroc - arm 2

Active Comparator: NRTI + maraviroc - arm 3


Treatment: drugs: arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors
NRTI + PI

Treatment: drugs: Arm 2 boosted protease inhibitors and maraviroc
PI + maraviroc

Treatment: drugs: Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc
NRTI + maraviroc

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>changes in proteinuria and albuminuria between baseline and week 96 - To compare the change in protein and albumin excretion as measured by the urine PCR and ACR through the kidneys between the randomised and standard of care (control) arm of MARCH.</outcome>
      <timepoint>96 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>changes in renal tubular function between baseline and week 96 - To evaluate the following aspects of renal function at baseline and changes within and between study groups:
Tubular function defined as proximal tubular function; ascending thick loop of Henle; distal tubular function; volume and renal potassium handling;
Non-tubular function i.e. eGFR; Urine albumin:creatinine ratio;
Determine factors associated with renal dysfunction within the cohort e.g. demographics, HIV related, HIV-treatment related, co-morbidities, concomitant medication (such as ACE inhibitors and ARB; PI/r co-administered with TDF); TDF use;</outcome>
      <timepoint>96 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Provision of written, informed consent for participation in the substudy

          -  Enrolled into the substudy either at or before the week 0 visit of the main study</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose />
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>76</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD</recruitmentstate>
    <hospital>St. Vincent's Hospital - Sydney</hospital>
    <hospital>Brisbane Sexual Health and HIV Service - Brisbane</hospital>
    <postcode>2010 - Sydney</postcode>
    <postcode>4000 - Brisbane</postcode>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Ciudad de Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Cologne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dusseldorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Nagoya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Tlalpan DF</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Lothian</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sussex</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Kirby Institute</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Chronic kidney disease (CKD) is an emerging problem in patients with treated HIV.
      Antiretroviral therapy associated renal dysfunction has been predominantly described in terms
      of reduced glomerular filtration (eGFR). Proteinuria is a key component of CKD and may occur
      in the absence of significant reductions in eGFR. This substudy is an exploration of changes
      in urinary protein excretion in a randomised, open-label study to evaluate the efficacy and
      safety of MVC as a switch for either nucleoside or nucleotide analogue reverse transcriptase
      inhibitors (N(t)RTI) or boosted protease inhibitors (PI/r) in HIV-1 infected individuals with
      stable, well-controlled plasma HIV-RNA while taking their first N(t)RTI + PI/r regimen of
      combination antiretroviral therapy (cART).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01637259</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Waldo Belloso, MD</name>
      <address>Hospital Italiano de Buenos Aires</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>